Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Skin Cancer01:30

Skin Cancer

Skin cancer is a type of cancer that occurs when there is an abnormal growth of skin cells, usually triggered by damage to the DNA within the skin cells. It is primarily caused by exposure to ultraviolet (UV) radiation from the sun or artificial sources like tanning beds. Skin cancer is the most common type of cancer worldwide, and its incidence continues to rise.
Basal Cell Carcinoma (BCC): BCC is the most common type of skin cancer, accounting for about 80% of cases. It typically develops in...
Treatment Resistent Cancers02:56

Treatment Resistent Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Branching architecture of tryptophan metabolism determines therapeutic vulnerability in acute myeloid leukemia.

Cell death & disease·2026
Same author

Antioxidant, pro-oxidant, cytotoxic and antimicrobial properties of selected plant phenolic compounds and resulting structure-activity relationships.

Scientific reports·2026
Same author

Computational discovery and preclinical validation of a novel nanodrug eEF2 kinase inhibitor for suppression of tumor growth in triple-negative breast cancer by induction of ferroptosis and apoptosis.

International journal of biological macromolecules·2026
Same author

Insulin-independent glucose uptake in skeletal muscle by coupled SGLT and Na,K-ATPase transport.

bioRxiv : the preprint server for biology·2026
Same author

Towards the Development of Effective Antioxidants-The Molecular Structure and Properties-Part 2.

Molecules (Basel, Switzerland)·2026
Same author

First-in-child phase I trial of p-STAT3 inhibitor WP1066 in pediatric brain tumor patients.

JCI insight·2025

Related Experiment Video

Updated: Jul 18, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

WP760, a melanoma selective drug.

Mingzhong Zheng1, Waldemar Priebe, Eugene T Walch

  • 1Department of Experimental Therapeutics, Unit 362, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston, TX 77030, USA.

Cancer Chemotherapy and Pharmacology
|December 30, 2006
PubMed
Summary

A novel bis-anthracycline, WP760, shows significant antimelanoma activity by inducing cell-cycle arrest and apoptosis in melanoma cells. WP760 demonstrates selectivity for melanoma, making it a promising candidate for further preclinical research.

More Related Videos

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Related Experiment Videos

Last Updated: Jul 18, 2026

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
07:41

A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis

Published on: March 8, 2022

A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells
06:09

Spatial and Temporal Control of Murine Melanoma Initiation from Mutant Melanocyte Stem Cells

Published on: June 7, 2019

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Melanoma exhibits chemoresistance, partly due to endogenous nitric oxide (NO) production.
  • Novel therapeutic agents are needed to overcome melanoma resistance mechanisms.

Purpose of the Study:

  • To investigate the specificity and antimelanoma mechanism of the novel bis-anthracycline, WP760.
  • To evaluate WP760's potential as an anti-melanoma agent.

Main Methods:

  • Methyl thiazolyl tetrazolium reduction (MTT) assay for cell growth inhibition.
  • Confocal microscopy for intracellular distribution.
  • Flow cytometry for cell-cycle arrest and apoptosis.
  • Western blotting for molecular analysis.

Main Results:

  • WP760 induced G(2)/M-phase cell-cycle arrest and apoptosis in melanoma cells at nanomolar concentrations.
  • WP760 demonstrated selectivity for melanoma over fibroblasts and lung cancer cells.
  • Molecular studies revealed p53 stabilization, upregulation of checkpoint kinase 2 and p27(Kip1), caspase-3 activation, and inhibition of inducible nitric oxide synthase (iNOS).

Conclusions:

  • WP760 activates the intrinsic apoptotic pathway in melanoma cells.
  • WP760 exhibits unique growth regulatory effects in melanoma.
  • WP760 is a promising candidate for further preclinical investigation.